Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | RECQL | P46063 | 1/20 | 0.59 |
| ▸ | MMP8 | P22894 | 1/20 | 0.59 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | PPID | Q08752 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | PTPRC | P08575 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28033792 | 0.86 | HDAC4 (0.47) | ALDH1A1RECQLMMP8PIN1POLB | |
| SCHEMBL3920792 | 0.85 | ESR1 (0.47) | ALDH1A1RECQLMMP8POLBNPSR1 | |
| SCHEMBL3629075 | 0.85 | LMNA (0.50) | ALDH1A1RECQLMMP8PIN1POLB | |
| SCHEMBL27954863 | 0.84 | PTPN1 (0.57) | ALDH1A1LMNAKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL25223158 | 0.83 | CYP3A4 (0.53) | ALDH1A1RECQLMMP8NPSR1LMNA | |
| SCHEMBL10021176 | 0.83 | ALDH1A1 (0.42) | ALDH1A1RECQLMMP8PIN1POLB | |
| SCHEMBL2008727 | 0.83 | TAAR1 (0.53) | ALDH1A1RECQLMMP8PIN1POLB | |
| SCHEMBL27167976 | 0.83 | LMNA (0.46) | ALDH1A1RECQLMMP8PIN1POLB | |
| SCHEMBL5806489 | 0.82 | ALDH1A1 (0.62) | ALDH1A1RECQLMMP8PIN1POLB | |
| SCHEMBL4419400 | 0.82 | ALDH1A1 (0.62) | ALDH1A1RECQLMMP8PIN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4622959-A1 | 2-AMINO-N-(4-AMINO-3,4-DIOXO-1-(2-OXOPYRROLIDIN-3-YL)BUTAN-2-YL)BENZAMIDE DERIVATIVES AS PROTEASE INHIBITORS FOR TREATING OR PREVENTING CORONAVIRUS INFECTION | Merck Sharp & Dohme LLC (US) | 2025-10-01 | — | — | EP | disclosed |
| US-20240228535-A1 | PROTEASE INHIBITORS FOR TREATING OR PREVENTING CORONAVIRUS INFECTION | MERCK SHARP & DOHME LLC (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240228535-A1 | PROTEASE INHIBITORS FOR TREATING OR PREVENTING CORONAVIRUS INFECTION | MERCK SHARP & DOHME LLC (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240228535-A1 | PROTEASE INHIBITORS FOR TREATING OR PREVENTING CORONAVIRUS INFECTION | MERCK SHARP & DOHME LLC (US) | 2024-07-11 | — | — | US | disclosed |
| WO-2024112621-A1 | 2-AMINO-N-(4-AMINO-3,4-DIOXO-1-(2-OXOPYRROLIDIN-3-YL)BUTAN-2-YL)BENZAMIDE DERIVATIVES AS PROTEASE INHIBITORS FOR TREATING OR PREVENTING CORONAVIRUS INFECTION | MERCK SHARP & DOHME LLC (US) | 2024-05-30 | — | — | WO | disclosed |
| US-8420669-B2 | Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the BETA2 adrenergic receptor | LABORATORIES ALMIRALL, S.A. (ES) | 2013-04-16 | — | — | US | disclosed |
| US-8420669-B2 | Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the BETA2 adrenergic receptor | LABORATORIES ALMIRALL, S.A. (ES) | 2013-04-16 | — | — | US | disclosed |
| US-8242177-B2 | Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the β2 adrenergic receptor | ALMIRALL, S.A. (ES) | 2012-08-14 | — | — | US | disclosed |
| US-8242177-B2 | Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the β2 adrenergic receptor | ALMIRALL, S.A. (ES) | 2012-08-14 | — | — | US | disclosed |
| US-20120115826-A2 | Derivatives of 4-(2-Amino-1-Hydroxyethyl) Phenol as Agonists of the Beta2 AdrenergicReceptor | LABORATORIOS ALMIRALL, S.A. (ES) | 2012-05-10 | — | — | US | disclosed |
| EP-2263998-A1 | Derivatives of 4-(2-amino-1-hydroxyethyl) phenol as agonists of the beta2 adrenergic receptor | Almirall S.A. (ES) | 2010-12-22 | — | — | EP | disclosed |
| US-20090042933-A1 | Derivatives of 4-(2-amino -1-hydroxyethyl)phenol as agonists of the Beta2 adrenergic receptor | ALMIRALL, S.A. (ES) | 2009-02-12 | — | — | US | disclosed |
| US-20090042933-A1 | Derivatives of 4-(2-amino -1-hydroxyethyl)phenol as agonists of the Beta2 adrenergic receptor | ALMIRALL, S.A. (ES) | 2009-02-12 | — | — | US | disclosed |
| EP-1885684-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL)PHENOL AS AGONISTS OF THE BETA-2 ADRENERGIC RECEPTOR | Laboratorios Almirall, S.A. (ES) | 2008-02-13 | — | — | EP | disclosed |
| WO-2006122788-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL)PHENOL AS AGONISTS OF THE β2 ADRENERGIC RECEPTOR | LABORATORIOS ALMIRALL, S.A. (ES) | 2006-11-23 | — | — | WO | disclosed |
| EP-0839798-A2 | Intermediates for preparating non-peptide retroviral protease inhibitors | ABBOTT LABORATORIES (US) | 1998-05-06 | — | — | EP | disclosed |
| US-5670675-A | Retroviral protease inhibiting compounds | ABBOTT LABORATORIES (US) | 1997-09-23 | — | — | US | disclosed |
| US-5545750-A | TREATING HUMAN IMMUNODEFICIENCY VIRUS | ABBOTT LABORATORIES (US) | 1996-08-13 | — | — | US | disclosed |
| US-5142056-A | Human immunodeficiency virus protease inhibitor | ABBOTT LABORATORIES (US) | 1992-08-25 | — | — | US | disclosed |
| EP-0402646-A1 | Retroviral protease inhibiting compounds | ABBOTT LABORATORIES (US) | 1990-12-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228535-A1 | PROTEASE INHIBITORS FOR TREATING OR PREVENTING CORONAVIRUS INFECTION | PRSS1, PRSS2, ACE2 | ALDH1A1 4236/4885RECQL 307/4885MMP8 550/4885 |
| US-20090042933-A1 | Derivatives of 4-(2-amino -1-hydroxyethyl)phenol as agonists of the Beta2 adrenergic receptor | ADRB2, ADRA2C, ADRB1 | ALDH1A1 2732/4885RECQL 1736/4885MMP8 4140/4885 |
| US-20120115826-A2 | Derivatives of 4-(2-Amino-1-Hydroxyethyl) Phenol as Agonists of the Beta2 AdrenergicReceptor | ADRB2, ADRB1, ADRA2C | ALDH1A1 378/4885RECQL 2915/4885MMP8 4347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.